Zavegepant Hydrochloride Patent Expiration

Zavegepant Hydrochloride is used for acute treatment of migraine with or without aura. It was first introduced by Pfizer Inc in its drug Zavzpret on Mar 9, 2023.


Zavegepant Hydrochloride Patents

Given below is the list of patents protecting Zavegepant Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zavzpret US8481546 CGRP receptor antagonist Oct 07, 2031 Pfizer
Zavzpret US7220862 Calcitonin gene related peptide receptor antagonists Jan 21, 2024

(Expired)

Pfizer
Zavzpret US7314883 Anti-migraine treatments Dec 05, 2023

(Expired)

Pfizer



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zavegepant Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Zavegepant Hydrochloride.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US8481546
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US8481546
Letter re PTE application to FDA or Dept of Agriculture 16 May, 2023 US8481546
Patent Term Extension Application under 35 USC 156 Filed 03 May, 2023 US8481546
Payment of Maintenance Fee, 8th Year, Large Entity 23 Dec, 2020 US8481546
Payment of Maintenance Fee, 12th Year, Large Entity 20 Jun, 2019 US7314883
Payment of Maintenance Fee, 12th Year, Large Entity 08 Nov, 2018 US7220862
Patent Issue Date Used in PTA Calculation 09 Jul, 2013 US8481546
Recordation of Patent Grant Mailed 09 Jul, 2013 US8481546
Email Notification 20 Jun, 2013 US8481546


Zavegepant Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List